Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most factual claims (approval status, indication categories, BTK inhibitor mechanism, lack of contraindications, common adverse reactions, manufacturer) are broadly consistent with typical labeling structure, but the dosage/administration, approval basis wording, side-effect listing details, and manufacturer claim are not directly supported by the provided label excerpts. One claim about FDA approval timing is not verifiable from the supplied label content.
Category Scores
Accurate Statements
Acalabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor.
No label excerpt provided in the prompt for the mechanism statement; however, this claim is not directly contradicted by the provided excerpts.
Acalabrutinib is approved for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Section 1.2: “CALQUENCE is indicated for the treatment of adult patients with MCL who have received at least one prior therapy.”
Acalabrutinib is approved for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Section 1.3: “CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).”
Common side effects of acalabrutinib include diarrhea, fatigue, headache, and bruising.
Section 6.1 includes adverse reactions in ≥30% including “diarrhea (36%), headache (35%).” Other items (fatigue, bruising) are not explicitly shown in the provided adverse-reaction excerpt.
Contraindications: None.
Section 4: “CONTRAINDICATIONS: None.”
Unsupported Statements
Acalabrutinib (Calquence) received FDA approval in October 2017.
No FDA approval date/timing is present in the supplied label excerpts.
FDA approval of acalabrutinib was based on data from clinical trials demonstrating its efficacy in MCL, CLL, and SLL.
The provided excerpts list indications and safety content but do not describe the specific basis of approval/evidence in the way asserted.
By inhibiting BTK, acalabrutinib disrupts signaling pathways essential for B-cell proliferation, trafficking, and survival.
No mechanistic description is included in the provided label excerpts.
Common side effects of acalabrutinib include fatigue and bruising.
The provided adverse reaction excerpt explicitly lists upper respiratory tract infection, diarrhea, headache, and musculoskeletal pain; fatigue and bruising are not explicitly supported in the excerpt provided.
Calquence (acalabrutinib) is manufactured by AstraZeneca.
No manufacturing/labelholder/manufacturer statement is present in the supplied excerpts.
Contradictions
Important Omissions
For any dosing-related claims (none were explicitly stated in the provided claims list), the label would specify “100 mg approximately every 12 hours” and administration instructions (swallow whole, do not open/break/chew).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some safety-related statements are partially supported (e.g., diarrhea and headache), but other common side effects listed (fatigue, bruising) are not explicitly supported by the excerpt. Non-supported claims about approval basis/timing and manufacturer do not directly change clinical safety, but unsupported mechanistic and side-effect details reduce label alignment and could lead to mischaracterization of expected adverse reactions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims are not supported by the provided label excerpts (FDA approval timing, approval basis wording, mechanistic pathway description, fatigue/bruising as common side effects, manufacturer).
Suggested Improvement
Restrict claims to label-supported text from the provided sections (especially Section 1 indications and Section 6 adverse-reaction excerpt) and avoid asserting approval date, mechanistic details, approval-evidence basis language, or manufacturer information unless present in the provided FDA label text.